Business Context and Reporting Period
This Form 8-K is a current report filed by Aerovate Therapeutics, Inc. (not Jade Biosciences, Inc.) on May 16, 2022. The filing serves to announce the company's financial results for the quarter ended March 31, 2022. The company is an emerging growth company incorporated in Delaware, with its common stock (AVTE) traded on The Nasdaq Global Market.
Key Financial Metrics
The provided text is a cover page and index for the filing and does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being contained within the press release furnished as Exhibit 99.1, which is not included in the input text.
Material Changes
The filing text does not provide specific data regarding material changes versus the prior comparable period. It only confirms that financial results for the quarter ended March 31, 2022, were announced.
Guidance, Outlook, and Risks
The text does not include management commentary, guidance, outlook, or specific risk factors. It notes that the information in this report and the attached press release is "furnished" and not "filed" for purposes of Section 18 of the Exchange Act, meaning it is not subject to the liabilities of that section unless expressly incorporated by reference.
Investor Verification Checklist
- Verify the correct company name: The filing is for Aerovate Therapeutics, Inc., despite the metadata request mentioning Jade Biosciences, Inc.
- Locate and review Exhibit 99.1 (the press release) to obtain actual financial figures for the quarter ended March 31, 2022.
- Confirm the company's status as an emerging growth company and its election regarding extended transition periods for accounting standards.
- Check the Nasdaq Global Market for the current trading status of ticker symbol AVTE.